tradingkey.logo
tradingkey.logo
Search

Nutriband Inc

NTRB
Add to Watchlist
3.600USD
+0.010+0.28%
Close 05/15, 16:00ETQuotes delayed by 15 min
43.76MMarket Cap
LossP/E TTM

Nutriband Inc

3.600
+0.010+0.28%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Nutriband Inc

Currency: USD Updated: 2026-05-15

Key Insights

Nutriband Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 127 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nutriband Inc's Score

Industry at a Glance

Industry Ranking
127 / 206
Overall Ranking
289 / 4482
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Nutriband Inc Highlights

StrengthsRisks
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.04M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.04M.
Overvalued
The company’s latest PE is -1.39, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 579.57K shares, increasing 15.48% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
15.000
Target Price
+317.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Nutriband Inc is 6.10, ranking 169 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 400.71K, representing a year-over-year decrease of 37.62%, while its net profit experienced a year-over-year decrease of 82.45%.

Score

Industry at a Glance

Previous score
6.10
Change
0

Financials

9.91

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.10

Operational Efficiency

2.64

Growth Potential

3.71

Shareholder Returns

7.12

Nutriband Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Nutriband Inc is 5.76, ranking 176 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -1.39, which is -18.62% below the recent high of -1.14 and -906.57% above the recent low of -14.04.

Score

Industry at a Glance

Previous score
5.76
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 127/206
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Nutriband Inc is 8.00, ranking 66 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 15.00, with a high of 15.00 and a low of 15.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
15.000
Target Price
+317.83%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

116
Total
6
Median
9
Average
Company name
Ratings
Analysts
Nutriband Inc
NTRB
1
Medtronic PLC
MDT
33
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
31
1
2
3
...
23

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Nutriband Inc is 6.56, ranking 128 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 4.11 and the support level at 3.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.52
Change
0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(1)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.070
Sell
RSI(14)
41.113
Neutral
STOCH(KDJ)(9,3,3)
13.202
Oversold
ATR(14)
0.200
High Vlolatility
CCI(14)
-103.811
Sell
Williams %R
85.292
Oversold
TRIX(12,20)
-0.308
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
3.598
Buy
MA10
3.728
Sell
MA20
3.850
Sell
MA50
3.872
Sell
MA100
4.162
Sell
MA200
5.257
Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Nutriband Inc is 3.00, ranking 133 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 4.77%, representing a quarter-over-quarter increase of 63.31%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Botgros (Vitalie)
3.22M
+4.28%
TII Jet Services, LDA
1.81M
+36.66%
Sheridan (Gareth)
1.76M
--
Glinka (Serguei)
1.12M
+35.64%
Melnik (Serguei)
939.42K
+14.50%
Goodman (Gerald)
86.33K
--
Geode Capital Management, L.L.C.
59.94K
--
Smith (Allan)
36.91K
-11.93%
Patrick (Jeff)
36.61K
--
1
2

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Nutriband Inc is 2.17, ranking 161 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.94. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
2.17
Change
0
Beta vs S&P 500 index
1.93
VaR
+9.57%
240-Day Maximum Drawdown
+67.72%
240-Day Volatility
+81.83%

Return

Best Daily Return
60 days
+10.27%
120 days
+16.04%
5 years
+157.80%
Worst Daily Return
60 days
-10.36%
120 days
-15.98%
5 years
-34.11%
Sharpe Ratio
60 days
-0.53
120 days
-0.84
5 years
+0.33

Risk Assessment

Maximum Drawdown
240 days
+67.72%
3 years
+67.72%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.82
3 years
-0.00
5 years
--
Skewness
240 days
+1.87
3 years
+1.81
5 years
+6.00

Volatility

Realised Volatility
240 days
+81.83%
5 years
--
Standardised True Range
240 days
+11.44%
5 years
--
Downside Risk-Adjusted Return
120 days
-129.24%
240 days
-129.24%
Maximum Daily Upside Volatility
60 days
+48.67%
Maximum Daily Downside Volatility
60 days
+43.82%

Liquidity

Average Turnover Rate
60 days
+0.09%
120 days
+0.18%
5 years
--
Turnover Deviation
20 days
-87.04%
60 days
-84.88%
120 days
-68.53%

Peer Comparison

Healthcare Equipment & Supplies
Nutriband Inc
Nutriband Inc
NTRB
5.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LivaNova PLC
LIVN
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bruker Corp
Bruker Corp
BRKR
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI